ConductScience.org, home

Paper39355199

Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.

Degirmenci M and 6 others. Breast Cancer (Dove Med Press), 2024. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study. Papers, record 39355199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39355199

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.
PubMed
Journal
Breast Cancer (Dove Med Press)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.21, provisional
iCite
Revised in PubMed
2024-10-03
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Degirmenci MMustafahttps://orcid.org/0000-0001-6988-9205
2Diniz GGulden
3Kahraman DSDudu Solakoglu
4Sahbazlar MMustafa
5Koral LLokman
6Varol UUmut
7Uslu RRuchanhttps://orcid.org/0000-0002-9584-6134

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120027191Molecular predictors of response to trastuzumab and lapatinib in breast cancer.Nat Rev Clin Oncol2010https://conductscience.org/library/papers/20027191PubMed
215809519A retrospective series of long-term survivors of metastatic breast cancer in complete remission.Oncology2005https://conductscience.org/library/papers/15809519PubMed
322172323PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.Ann Oncol2012https://conductscience.org/library/papers/22172323PubMed
422767587Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.Ann Oncol2012https://conductscience.org/library/papers/22767587PubMed
527777963
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.
J Immunol Res2016https://conductscience.org/library/papers/27777963PubMed
611251000
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
J Clin Oncol2001https://conductscience.org/library/papers/11251000PubMed
711248153Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001https://conductscience.org/library/papers/11248153PubMed
88708708Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.J Clin Oncol1996https://conductscience.org/library/papers/8708708PubMed
98943669Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study.Eur J Cancer1996https://conductscience.org/library/papers/8943669PubMed
1023908178Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.Ann Oncol2013https://conductscience.org/library/papers/23908178PubMed
1127143924Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China.Onco Targets Ther2016https://conductscience.org/library/papers/27143924PubMed
1218038883When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?Tumori2007https://conductscience.org/library/papers/18038883PubMed
1335804943Immunological Landscape of HER-2 Positive Breast Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/35804943PubMed
1432222891Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.Breast Cancer2020https://conductscience.org/library/papers/32222891PubMed
1534339645Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.Lancet Oncol2021https://conductscience.org/library/papers/34339645PubMed
1616683005Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.Nat Clin Pract Oncol2006https://conductscience.org/library/papers/16683005PubMed
1721115860
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
J Clin Oncol2011https://conductscience.org/library/papers/21115860PubMed
1837783133Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study.Breast2023https://conductscience.org/library/papers/37783133PubMed
1920210247Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report.Tumori2009https://conductscience.org/library/papers/20210247PubMed
2026648738Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study.Onco Targets Ther2015https://conductscience.org/library/papers/26648738PubMed

See all 42 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
40437918Evaluation of Tissue Expression of HMBG1 Protein in Patients With Breast Cancer.Eur J Breast Health2025https://conductscience.org/library/papers/40437918

Source PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FOXP350943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39355199

GET https://conductscience.org/api/papers/v1/39355199/references?page=2